Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–77.

Article  CAS  PubMed  Google Scholar 

Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and Function of T Regulatory Cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290–300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab Monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–19.

Article  CAS  PubMed  Google Scholar 

Chami B, Okuda M, Moayeri M, Pirenne F, Hidaka Y, Nambiar A, et al. Anti-CD38 monoclonal antibody interference with blood compatibility testing: differentiating isatuximab and daratumumab via functional epitope mapping. Transfusion. 2022;62:2334–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–8.

Article  PubMed  Google Scholar 

Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yadav S, Gundeti S, Bhave A, Deb U, Dixit J, Mishra K. Role of daratumumab in the frontline management of multiple myeloma: a narrative review. Expert Rev Hematol. 2023;16:743–60.

Article  CAS  PubMed  Google Scholar 

Pandit-Taskar N. Functional imaging methods for Assessment of minimal residual disease in multiple myeloma: current status and novel ImmunoPET based methods. Semin Hematol. 2018;55:22–32.

Article  PubMed  PubMed Central  Google Scholar 

Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, et al. Identifying CD38 + cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020;4:5194–202.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ulaner GA, Sobol NB, O’Donoghue JA, Kirov AS, Riedl CC, Min R, et al. CD38-targeted Immuno-PET of multiple myeloma: from Xenograft models to First-in-human imaging. Radiology. 2020;295:606–15.

Article  PubMed  Google Scholar 

Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, et al. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021;48:2749–60.

Article  CAS  PubMed  Google Scholar 

Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, et al. CD38-Targeted theranostics of lymphoma with 89Zr/177Lu-Labeled daratumumab. Adv Sci (Weinh). 2021;8:2001879.

Article  CAS  PubMed  Google Scholar 

Kang L, Li C, Yang Q, Sutherlin L, Wang L, Chen Z, et al. 64Cu-labeled daratumumab F(ab’)2 fragment enables early visualization of CD38-positive lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:1470–81.

Article  CAS  PubMed  Google Scholar 

Shi L, Chen B, Liu T, Li L, Hu B, Li C, et al. 99mTc-CD3813: a nanobody-based single Photon Emission Computed Tomography Radiotracer with clinical potential for Myeloma Imaging and evaluation of CD38 expression. Mol Pharm. 2022;19:2583–94.

Article  CAS  PubMed  Google Scholar 

Chen Z, Yang Q, Song L, Qiu Y, Wang T, Wu S et al. Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Mol Pharm. 2024.

Thangaraj JL, Ahn S-Y, Jung S-H, Vo M-C, Chu T-H, Thi Phan M-T, et al. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol. 2021;18:1652–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Z, Huang W, Zhang M, Huo Y, Li F, Song L, et al. Minocycline-loaded nHAP/PLGA microspheres for prevention of injury-related corneal angiogenesis. J Nanobiotechnol. 2024;22:134.

Article  CAS  Google Scholar 

Yang Q, Chen Z, Qiu Y, Huang W, Wang T, Song L, et al. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:1246–60.

Article  CAS  PubMed  Google Scholar 

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.

PubMed  Google Scholar 

The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332.

Google Scholar 

Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, et al. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Ann Hematol. 2021;100:1059–63.

Article  CAS  PubMed  Google Scholar 

van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29.

Article  PubMed  Google Scholar 

Ehlerding EB, England CG, Jiang D, Graves SA, Kang L, Lacognata S, et al. CD38 as a PET imaging target in Lung Cancer. Mol Pharm. 2017;14:2400–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caserta E, Chea J, Minnix M, Poku EK, Viola D, Vonderfecht S, et al. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018;131:741–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S, England CG, Ehlerding EB, Kutyreff CJ, Engle JW, Jiang D, et al. ImmunoPET imaging of CD38 expression in hepatocellular carcinoma using 64Cu-labeled daratumumab. Am J Transl Res. 2019;11:6007–15.

CAS  PubMed  PubMed Central  Google Scholar 

Jin B-K, Odongo S, Radwanska M, Magez S, Nanobodies. A review of Generation, Diagnostics and therapeutics. Int J Mol Sci. 2023;24:5994.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging early myeloma. Leuk Lymphoma. 2013;54:1355–63.

Article  PubMed  Google Scholar 

Zheleznyak A, Tang R, Duncan K, Manion B, Liang K, Xu B, et al. Development of New CD38 targeted peptides for Cancer Imaging. Mol Imaging Biol. 2024;26:738–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma AK, Gupta K, Mishra A, Lofland G, Marsh I, Kumar D, et al. CD38-Specific Gallium-68 labeled peptide Radiotracer enables pharmacodynamic monitoring in multiple myeloma with PET. Adv Sci (Weinh). 2024;11:e2308617.

Article  PubMed  Google Scholar 

Cooper BM, Iegre J, O’ Donovan DH, Ölwegård Halvarsson M, Spring DR. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev. 2021;50:1480–94.

Article  CAS  PubMed  Google Scholar 

Rodríguez-Laval V, Lumbreras-Fernández B, Aguado-Bueno B, Gómez-León N. Imaging of multiple myeloma: Present and Future. J Clin Med. 2024;13:264.

Article